GELNIQUE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GELNIQUE (GELNIQUE).
GELNIQUE (oxybutynin) is a competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3), primarily M3 receptors in the detrusor muscle of the bladder, reducing bladder contractions and increasing bladder capacity.
| Metabolism | Extensively metabolized by cytochrome P450 enzymes, primarily CYP3A4, to active and inactive metabolites; undergoes first-pass metabolism. |
| Excretion | Approximately 75% of the dose is excreted renally as unchanged drug and metabolites (primarily N-desethyloxybutynin), with about 25% excreted in feces via biliary elimination. |
| Half-life | Terminal elimination half-life is approximately 12-13 hours for oxybutynin and 8-10 hours for the active metabolite N-desethyloxybutynin, allowing for once-weekly transdermal dosing. |
| Protein binding | Oxybutynin is approximately 90-95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | The apparent volume of distribution is approximately 2-3 L/kg, indicating extensive tissue distribution beyond plasma volume. |
| Bioavailability | Transdermal: approximately 100% bioavailability relative to IV, with steady-state concentrations achieved by day 3-4. |
| Onset of Action | Transdermal: Clinical effect is observed within 24-48 hours after application, with steady-state concentrations achieved by day 3-4. |
| Duration of Action | Each application provides continuous delivery for 7 days, with sustained plasma concentrations over the wear period. Clinical effect persists for the full week of wear. |
| Molecular Weight | 357.49 |
Apply 1 gram (1 sachet) of gel once daily to clean, dry, intact skin on the abdomen, upper arms, shoulders, or thighs. Each gram contains 100 mg oxybutynin.
| Dosage form | GEL |
| Renal impairment | No specific dose adjustment for GFR; use caution in severe renal impairment (CrCl <30 mL/min) due to potential accumulation. |
| Liver impairment | Contraindicated in Child-Pugh Class C cirrhosis; no specific recommendations for Class A or B, but use with caution due to increased systemic exposure. |
| Pediatric use | Not approved for pediatric patients (safety and efficacy not established). |
| Geriatric use | Start at the lowest effective dose (1 gram daily) due to increased risk of anticholinergic side effects (e.g., cognitive impairment, falls). Monitor renal function as elderly often have reduced GFR. |
| 1st trimester | Use only if potential benefit outweighs risk; animal studies show risk and no adequate human studies (Pregnancy Category C). |
| 2nd trimester | Use only if potential benefit outweighs risk; anticholinergic effects may cause fetal tachycardia or other effects. |
| 3rd trimester | Use only if potential benefit outweighs risk; risk of premature labor due to oxytocic effects? (Note: GELNIQUE contains oxybutynin, which has minor oxytocic activity). |
Clinical note
Comprehensive clinical and safety monograph for GELNIQUE (GELNIQUE).
| Placental transfer | Oxybutynin crosses the placenta; limited data but expected to cross due to molecular weight <500 Da. |
| Breastfeeding | Oxybutynin is excreted into breast milk in small amounts; use with caution in nursing mothers, especially with neonates or preterm infants due to risk of anticholinergic effects (dryness, constipation, drowsiness). |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to oxybutynin or any componentUrinary retentionGastric retentionUncontrolled narrow-angle glaucoma
| Precautions | May cause angioedema requiring immediate treatment, Exacerbation of symptoms in patients with myasthenia gravis, Decreased gastrointestinal motility in patients with ulcerative colitis or intestinal atony, Heat prostration in hot environments due to decreased sweating, Central nervous system effects including dizziness, somnolence, and confusion, Caution in patients with impaired renal or hepatic function, May worsen urinary retention, gastric retention, uncontrolled narrow-angle glaucoma |
| Food/Dietary | No specific food interactions reported. However, alcohol may enhance drowsiness and other central nervous system effects; limit or avoid alcohol consumption. |
Loading safety data…
| Lactation Rating | L3 - Moderate Safety |
| Teratogenic Risk | Pregnancy Category B. No evidence of fetal harm in animal studies. No adequate well-controlled studies in pregnant women. Use only if clearly needed. First trimester: theoretical risk based on anticholinergic effects; avoid unless necessary. Second/third trimester: increased risk of preterm labor due to oxybutynin's tocolytic properties? No direct teratogenicity reported. |
| Fetal Monitoring | Monitor fetal heart rate and uterine activity during labor if used. No specific monitoring required otherwise. |
| Fertility Effects | No known effects on fertility. Animal studies show no impairment of fertility at clinically relevant doses. |
| Clinical Pearls | GELNIQUE (oxybutynin chloride 10% gel) is a topical anticholinergic for overactive bladder. Apply to clean, dry, intact skin on the abdomen, upper arms/shoulders, or thighs; rotate sites to minimize local irritation. Avoid application to recently shaved or damaged skin. Onset of action may take several weeks. Caution in patients with narrow-angle glaucoma, urinary retention, or gastrointestinal obstructive disorders. Anticholinergic side effects (dry mouth, constipation, blurred vision) may be less than with oral oxybutynin but still occur. Use sunscreen if administering to exposed areas due to potential skin reactions. |
| Patient Advice | Apply the gel once daily at the same time each day to clean, dry, intact skin on the abdomen, upper arms/shoulders, or thighs. · Rotate application sites to reduce risk of skin irritation; do not apply to the same site on consecutive days. · Wash hands immediately after application to avoid transferring the gel to eyes or mucous membranes. · Avoid bathing, swimming, or showering for at least 1 hour after application to ensure absorption. · Do not apply to open wounds, sunburned, or irritated skin. · If you experience severe dry mouth, constipation, blurred vision, or difficulty urinating, contact your healthcare provider. · GELNIQUE may cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how the medication affects you. · Store at room temperature away from heat and moisture; keep out of reach of children and pets. |